Diabetic Gastroparesis Treatment Market | Global Players – Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Vanda Pharmaceuticals, F. Hoffmann-La Roche Ltd, CINRX

Diabetic Gastroparesis Treatment Market

In Diabetic Gastroparesis Treatment Market report, a systematic investment analysis has been performed which forecasts impending opportunities for the market players. The statistical and numerical data that has been included in this market report is represented with the tables, graphs and charts which eases the understanding of facts and figures. A proficient data and excellent forecasting techniques used in this report are synonymous with accurateness and correctness. Diabetic Gastroparesis Treatment Market report is a painstaking analysis of existing scenario of the market which covers several market dynamics. The market study of this global Diabetic Gastroparesis Treatment Market business report takes into consideration market attractiveness analysis where each segment is benchmarked based on its market size, growth rate & general attractiveness.

Get Exclusive Sample Copy of This Report Here

Global diabetic gastroparesis treatment market is expected to grow at a healthy CAGR in the forecast period of 2019-2026. Emergence of drugs used to treat diabetic gastroparesis and high demand of disease specific novel therapies are the key factors that fueling the market growth.

Few of the major competitors currently working in the global diabetic gastroparesis treatment market are Theravance Biopharma, Allergan, GlaxoSmithKline plc, Endologic, Evoke Pharma, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Vanda Pharmaceuticals, F. Hoffmann-La Roche Ltd, CINRX, Ironwood Pharmaceuticals, Inc, ANI Pharmaceuticals, Inc, Bausch Health, RHYTHM PHARMACEUTICALS, INC, Teva Pharmaceutical Industries Ltd, WOCKHARDT,  Fresenius Kabi AG, Pfizer Inc, Ipca Laboratories Ltd, Vintage Labs and others

Read Complete Details with TOC Here

Market Definition: Global Diabetic Gastroparesis Treatment Market

Gastroparesis is also called as delayed gastric emptying is condition of abnormal gastric motility which results in slow gastric emptying. Gastroparesis associated with diabetes is known as Diabetic Gastroparesis (DGP). Type 1 and type 2 diabetes can damage the vagus nerve, which controls the muscles of the stomach. The delay in gastric empty can worsen a patient with diabetes by making it more difficult to manage the blood sugar. People with diabetic gastropareses often experience heartburn, nausea, vomiting of undigested food, loss of appetite etc.

Segmentation: Global Diabetic Gastroparesis Treatment Market

Diabetic Gastroparesis Treatment Market : By Indication Type

  • Compensated Gastroparesis
  • Gastric Failure

Diabetic Gastroparesis Treatment Market : By Treatment

  • Medication
  • Surgery

Diabetic Gastroparesis Treatment Market : By Drugs

  • Gastroprokinetic Agents
  • Antiemetic Agents
  • Botulinum Toxin
  • Others

Diabetic Gastroparesis Treatment Market : By Route of Administration

  • Oral
  • Injectable

Diabetic Gastroparesis Treatment Market : By End Users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Diabetic Gastroparesis Treatment Market : By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Diabetic Gastroparesis Treatment Market : By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Key Developments in the Diabetic Gastroparesis Treatment Market:

  • In May 2019, Allergan expanded PLEDGE program with a fifth study with relamorelin, a ghrelin agonist being studied for the treatment of diabetic gastroparesis (DG). The relamorelin is currently in the phase II/II study. If trial successful it will change treatment paradigms across gastroenterology and improve the millions of people suffering from the debilitating effects of diabetic gastroparesis.
  • In December 2016, Theravance Biopharma received Fast Track designation from the FDA for velusetrag (TD-5108), an oral once-daily selective 5-hydroxtryptamine 4 (5-HT4) receptor agonist for the treatment of symptoms associated with idiopathic and diabetic gastroparesis. With this designation enables the company to accelerate the development process which helps patients to have access on the treatment as quickly as possible.

Diabetic Gastroparesis Treatment Market Drivers

  • Vulnerable diabetic population worldwide is fueling the growth of this market
  • Increase in special designation from the regulatory authorities is drive the market
  • Huge financial support to the researchers for developing novel intervention is boosting the market growth
  • High demand of disease specific novel treatment can also act as a market driver

Diabetic Gastroparesis Treatment Market Restraints

  • Limited operating revenue opportunities for research and development of targeted therapies by many pharmaceuticals is acting as a challenging factor for the growth of this market
  • Low healthcare budget in some developing countries is hamper the market growth

Competitive Analysis:Diabetic Gastroparesis Treatment Market

Global Diabetic Gastroparesis treatment market is highly fragmented and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. The report includes market shares of   Global Diabetic Gastroparesis treatment market for Global, Europe, North America, Asia-Pacific, South America and Middle East & Africa.

Opportunities in the Diabetic Gastroparesis Treatment Market Report :

  1. Comprehensive quantitative analysis of the industry is provided for the period of 2020-2026 to assist stakeholders to capitalize on the prevailing market opportunities.
  2. Comprehensive analysis of the factors that drive and restrict the market growth is provided in the Diabetic Gastroparesis Treatment Market report.
  3. Extensive analysis of the key segments of the industry helps in understanding the trends in types of point of care test across regional.
  4. Extensive analysis of the key segments of the industry helps in understanding the trends in types of point of care test across Global.

To Get This Report at an Attractive Cost, Click Here

About Data Bridge Market Research:

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475

Back to top button